INT 767

Drug Profile

INT 767

Alternative Names: Dual FXR/TGR5 agonists - Intercept Pharmaceuticals; FXR & TGR5 BA-derived backups - Intercept Pharmaceuticals; INT-767

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intercept Pharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Bile acids and salts; Cholanes; Small molecules; Sulfates
  • Mechanism of Action Farnesoid X-activated receptor agonists; G protein-coupled receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatic fibrosis
  • Preclinical Diabetic nephropathies; Non-alcoholic steatohepatitis
  • No development reported Metabolic disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Metabolic-disorders in USA (PO)
  • 04 May 2017 Intercept Pharmaceuticals plans a phase II trial for Non-alcoholic steatohepatitis in the second half of 2017
  • 11 Nov 2016 Preclinical trials in Non-alcoholic steatohepatitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top